Alzheimer’s drug Leqem­bi gets full OK; Biotech’s H1 by the num­bers; Bring­ing Leerink back; Against AI over­hype; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Long­time read­ers would be fa­mil­iar with our an­nu­al spe­cial re­port hon­or­ing women in bio­phar­ma R&D. This year we’ve moved the pub­li­ca­tion of the pro­files and the ac­com­pa­ny­ing event to Ju­ly. We would love to see you there — you can find more de­tails here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.